These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 1720589)

  • 1. Protection of BALB/c mice from respiratory syncytial virus infection by immunization with a synthetic peptide derived from the G glycoprotein.
    Trudel M; Nadon F; Séguin C; Binz H
    Virology; 1991 Dec; 185(2):749-57. PubMed ID: 1720589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic peptides corresponding to the F protein of RSV stimulate murine B and T cells but fail to confer protection.
    Trudel M; Stott EJ; Taylor G; Oth D; Mercier G; Nadon F; Séguin C; Simard C; Lacroix M
    Arch Virol; 1991; 117(1-2):59-71. PubMed ID: 1706591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV.
    Connors M; Collins PL; Firestone CY; Sotnikov AV; Waitze A; Davis AR; Hung PP; Chanock RM; Murphy BR
    Vaccine; 1992; 10(7):475-84. PubMed ID: 1609551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapping an antibody-binding site and a T-cell-stimulating site on the 1A protein of respiratory syncytial virus.
    Nicholas JA; Mitchell MA; Levely ME; Rubino KL; Kinner JH; Harn NK; Smith CW
    J Virol; 1988 Dec; 62(12):4465-73. PubMed ID: 2460636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposome encapsulation of a soluble recombinant fragment of the respiratory syncytial virus (RSV) G protein enhances immune protection and reduces lung eosinophilia associated with virus challenge.
    Mader D; Huang Y; Wang C; Fraser R; Issekutz AC; Stadnyk AW; Anderson R
    Vaccine; 2000 Jan; 18(11-12):1110-7. PubMed ID: 10590333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment.
    Power UF; Plotnicky-Gilquin H; Huss T; Robert A; Trudel M; Ståhl S; Uhlén M; Nguyen TN; Binz H
    Virology; 1997 Apr; 230(2):155-66. PubMed ID: 9143271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease.
    Murphy BR; Sotnikov A; Paradiso PR; Hildreth SW; Jenson AB; Baggs RB; Lawrence L; Zubak JJ; Chanock RM; Beeler JA
    Vaccine; 1989 Dec; 7(6):533-40. PubMed ID: 2692334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxic T cells specific for a single peptide on the M2 protein of respiratory syncytial virus are the sole mediators of resistance induced by immunization with M2 encoded by a recombinant vaccinia virus.
    Kulkarni AB; Collins PL; Bacik I; Yewdell JW; Bennink JR; Crowe JE; Murphy BR
    J Virol; 1995 Feb; 69(2):1261-4. PubMed ID: 7815502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus.
    Stott EJ; Taylor G; Ball LA; Anderson K; Young KK; King AM; Wertz GW
    J Virol; 1987 Dec; 61(12):3855-61. PubMed ID: 3316707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies.
    Connors M; Kulkarni AB; Collins PL; Firestone CY; Holmes KL; Morse HC; Murphy BR
    J Virol; 1992 Feb; 66(2):1277-81. PubMed ID: 1731105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic effect of immunization with a peptide cocktail inducing antibody, helper and cytotoxic T-cell responses on protection against respiratory syncytial virus.
    Hsu SC; Chargelegue D; Obeid OE; Steward MW
    J Gen Virol; 1999 Jun; 80 ( Pt 6)():1401-1405. PubMed ID: 10374957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective immune responses induced by the immunization of mice with a recombinant bacteriophage displaying an epitope of the human respiratory syncytial virus.
    Bastien N; Trudel M; Simard C
    Virology; 1997 Jul; 234(1):118-22. PubMed ID: 9234952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The envelope proteins from purified respiratory syncytial virus protect mice from intranasal virus challenge.
    Levine S; Dillman TR; Montgomery PC
    Proc Soc Exp Biol Med; 1989 Apr; 190(4):349-56. PubMed ID: 2928348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the ability of formalin-inactivated respiratory syncytial virus, immunopurified F, G and N proteins and cell lysate to enhance pulmonary changes in Balb/c mice.
    Vaux-Peretz F; Chapsal JM; Meignier B
    Vaccine; 1992; 10(2):113-8. PubMed ID: 1539464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G.
    Openshaw PJ; Clarke SL; Record FM
    Int Immunol; 1992 Apr; 4(4):493-500. PubMed ID: 1591217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The purification of four respiratory syncytial virus proteins and their evaluation as protective agents against experimental infection in BALB/c mice.
    Routledge EG; Willcocks MM; Samson AC; Morgan L; Scott R; Anderson JJ; Toms GL
    J Gen Virol; 1988 Feb; 69 ( Pt 2)():293-303. PubMed ID: 3339327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization with a peptide derived from the G glycoprotein of bovine respiratory syncytial virus (BRSV) reduces the incidence of BRSV-associated pneumonia in the natural host.
    Bastien N; Taylor G; Thomas LH; Wyld SG; Simard C; Trudel M
    Vaccine; 1997; 15(12-13):1385-90. PubMed ID: 9302749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete protection of mice from respiratory syncytial virus infection following mucosal delivery of synthetic peptide vaccines.
    Bastien N; Trudel M; Simard C
    Vaccine; 1999 Feb; 17(7-8):832-6. PubMed ID: 10067688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of feline leukaemia virus-neutralizing antibodies by immunization with synthetic peptides derived from the FeLV env gene.
    Weijer K; Pfauth A; van Herwijnen R; Jarrett O; Meloen RH; Tomee C; Osterhaus AD
    Vaccine; 1993; 11(9):946-56. PubMed ID: 7692683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic and mucosal immunity to respiratory syncytial virus induced by recombinant Streptococcus gordonii surface-displaying a domain of viral glycoprotein G.
    Falcone V; Mihm D; Neumann-Haefelin D; Costa C; Nguyen T; Pozzi G; Ricci S
    FEMS Immunol Med Microbiol; 2006 Oct; 48(1):116-22. PubMed ID: 16965359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.